What Free Information Resources Are Available for Breast Cancer Patients? (2026 Edition)

Breast cancer patients can access several resources at no cost: the National Cancer Information Center (cancer.go.kr), National Cancer Center Korea's (ncc.re.kr) national cancer registry statistics, the US NCCN's patient guidelines, the US National Cancer Institute's (NCI) follow-up care guidance, and our platform's Step 1 inquiry and video consultation — all of which remain free through the consultation stage.

Key Summary

• The National Cancer Information Center (cancer.go.kr) is a public-agency resource that provides general information on cancer diagnosis and treatment free of charge.
• National Cancer Center Korea's Central Cancer Registry publishes the National Cancer Registry Statistics 2019–2023, showing a 94.7% 5-year relative survival rate for breast cancer in Korea. This figure represents nationwide statistics, not results from any specific hospital.
• The US NCCN's patient guidelines (nccn.org/patientresources) are free, English-language patient education materials explaining how treatment varies according to subtype and biomarkers.
• On our platform, the Step 1 inquiry and 30-minute video consultation are free, while the Step 2 remote review (pre-arrival review) (KRW 1,000,000, about US$730) is deducted from treatment costs if a treatment contract is signed afterward.
• General principles of post-treatment follow-up and criteria for when to contact your care team are also available free of charge through the National Cancer Information Center and US National Cancer Institute (NCI) resources.

What Can You View for Free on the National Cancer Information Center?

• The National Cancer Information Center is a public cancer information site operated by the Korean government, offering general explanations about cancer at no cost.
• The National Cancer Registry Statistics 2019–2023, published by National Cancer Center Korea's Central Cancer Registry, is the source of the 94.7% 5-year relative survival rate for breast cancer in Korea. This figure is a population average and does not predict individual outcomes.
• The same agency's materials also outline general follow-up principles for breast cancer (relatively frequent visits in the first 2–3 years, with intervals gradually lengthening afterward). However, specific test schedules and items vary by cancer type and individual treatment, so these are determined by your care team.

What Kind of Resource Is the US NCCN Patient Guideline?

• The NCCN patient guideline is a patient education resource developed by the US National Comprehensive Cancer Network, covering how treatment differs based on biomarker testing (ER, PR, HER2, etc.).
• It is available in English and can be downloaded free of charge, serving as a reference for English-speaking patients seeking to understand the importance of subtype and biomarker testing before treatment.
• Because it covers multiple cancer types, it broadly explains that pre-treatment biomarker testing is a standard procedure, not only for breast cancer.
• However, this material provides general information and does not substitute for an individual diagnosis or prescription.

Where Can You Find Free Information on Post-Treatment Follow-Up?

• The US National Cancer Institute (NCI) describes post-treatment follow-up care as a process of regularly meeting with your care team after treatment ends to monitor changes in health, generally every 3–4 months for the first 2–3 years and once or twice a year thereafter. Individual schedules vary depending on cancer type, treatment received, and overall health status.
• NCI materials, available free of charge, also recommend notifying your care team right away — rather than waiting for the next scheduled appointment — if you experience new or persistent pain, lumps, bleeding, weight loss, shortness of breath, a persistent cough, new bone pain, or a fever of 38°C or higher.
• The same materials state that your oncologist or care team should provide a written treatment summary and follow-up recommendations.

What Free Procedures Does Our Platform Provide?

• Step 1 inquiry is free. Contact us via email or our consultation channel, and a coordinator will respond within 24 hours, helping organize the records you need and outline the process.
• If you prefer, you can also book a free 30-minute video consultation to check in advance what materials will be needed.
• Step 2, the remote review (pre-arrival review), is a paid step (KRW 1,000,000, about US$730) that provides a written opinion within 5 business days of your records being complete. This fee is later deducted from treatment costs if you sign a treatment contract.
• Step 1 serves as a free resource to understand the overall process and the list of required documents before moving on to Step 2.

FAQ — Can I Make Treatment Decisions Based on These Resources?

No. These resources are intended to provide general medical information and do not substitute for an individual diagnosis or treatment decision. Because breast cancer treatment — including surgical sequencing and medication — varies significantly depending on hormone receptor and HER2 test results, the actual treatment direction must be determined in consultation with your care team.

FAQ — Where Can I Check Survival Rate Figures for Free?

You can view the 94.7% 5-year relative survival rate for breast cancer in Korea free of charge through the National Cancer Registry Statistics 2019–2023 (National Cancer Center Korea, Central Cancer Registry). For comparison, the US SEER 2016–2022 data report a 5-year relative survival rate of 91.9% for female breast cancer. Both figures represent nationwide statistics rather than results from any specific hospital, and neither predicts individual outcomes.

Sources and Notes

• This article was written with reference to the National Cancer Registry Statistics 2019–2023 (National Cancer Center Korea), the National Cancer Information Center, the US NCCN patient guidelines, SEER statistical data, the US National Cancer Institute's (NCI) post-treatment follow-up care guidance, and our platform's treatment journey and remote review (pre-arrival review) information.
• This content is intended for general medical information purposes only. Diagnosis, treatment methods, and outcomes may vary depending on individual circumstances. Accurate diagnosis and treatment must be determined through consultation with your care team.